GSK signs agreement with U.S. government to lower drug prices and expand access for Americans

LONDON - GSK plc (LSE/NYSE: GSK) announced that it has entered into an agreement with the U.S. Administration to lower the cost of prescription medicines for American patients, including GSK's…

NNR December 22, 2025

London Stock Exchange

GSK receives expanded Shingrix approval in China

BEIJING: GSK plc (LSE/NYSE: GSK) said Tuesday that China’s National Medical Products Administration has approved Shingrix, its recombinant zoster vaccine (RZV), for use in adults aged 18 and older who…

NNR October 14, 2025

London Stock Exchange

Luke Miels appointed CEO designate for GSK

LONDON: GSK plc (LSE/NYSE: GSK) today announced that Luke Miels is appointed CEO Designate, GSK. He will assume full responsibilities as CEO and join the Board on 1st January 2026.…

Bernice Miles September 29, 2025

London Stock Exchange

GSK to invest $30 billion in R&D and manufacturing in the United States over next 5 years

· Includes new $1.2 billion investment announced today in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs · New facilities will bridge R&D and manufacturing across…

Bernice Miles September 17, 2025

London Stock Exchange

GSK signals confidence with robust Q2 as specialty medicines surge

Operating profit up 33% as strong product mix and R&D drive gains GSK Plc reported another solid quarter in Q2 2025, underscoring its trajectory toward the top end of its…

Ali Mirza July 30, 2025

London Stock Exchange

GSK, China’s Hengrui Pharma ink $500m deal to co-develop 12 innovative medicines

LONDON: GSK plc announced Monday that it has entered into agreements with China-based Hengrui Pharma to co-develop up to 12 innovative medicines spanning respiratory, immunology, inflammation and oncology indications, marking…

Ali Mirza July 28, 2025

London Stock Exchange

Japan approves first RSV vaccine for adults 50-59

LONDON: GSK plc (LSE/NYSE: GSK) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus…

NNR November 22, 2024

London Stock Exchange

GSK acquires full rights to mRNA candidate vaccines

GSK acquires full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and COVID-19, including combinations

Bernice Miles July 3, 2024

London Exchange London Stock Exchange

GSK intends to completely offload Haleon shares

LONDON, UK: GSK plc (LSE/NYSE: GSK) it intends to sell approximately 385 million ordinary shares in Haleon, equivalent to approximately 4.2% of Haleon's issued share capital and representing GSK's entire…

NNR May 16, 2024

London Exchange

GSK completes sale of shares in Haleon

LONDON: GSK plc announced that, further to its announcement on 16 January 2024, GSK has agreed to sell 300m ordinary shares in Haleon plc at a price of 326 pence…

NNR January 17, 2024

London Exchange

GSK to buy Aiolos Bio for $1.4 billion, boosting its respiratory portfolio

GSK completes acquisition of Aiolos Bio LONDON: GSK plc, a global pharmaceutical company, announced today that it has agreed to acquire Aiolos Bio, Inc., a clinical-stage biotech firm developing a…

NNR January 9, 2024

London Exchange

GSK agrees to acquire Sierra Oncology for $1.9bn

LONDON, UK: GlaxoSmithKline plc (LSE: GSK) and Sierra Oncology Inc (Nasdaq: SRRA) have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused…

Bernice Miles April 13, 2022